Ivantis Finds $25M For Microstent Surgery Devices

Irvine-based medical device developer Ivantis, which is developing microstents for minimally invasive glaucoma surgery, has raised $25M in a Series C funding, the company announced today. The funding was led by RA Capital Management, a new investor, and also included Merieux Developpement, along with existing investors. The company said the funding gives it runway until 2020, and support commercialization of its product in the United States. The company says it is anticipating approval by the FDA in 2018 of its device. Dave Van Meter is President and CEO of Ivantis. Microstents are used in glaucoma surgery to relieve intraocular pressure in a patient's eye--the root cause of glaucoma. Untreated, that pressure on a patient's optic nerve can cause permanent loss of vision.